Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorDouglas Scharre
About this trial
The study is designed to characterize the clinical, neuropsychological, polysomnographic, and neuroimaging findings among subjects with Alzheimer's disease, Lewy Body dementia, and Parkinsons' Disease.
Eligibility criteria
Qualifiers
Subjects must meet the standard clinical criteria of the syndromes of interest
All subjects must have enough cognitive abilities to complete study procedures, which will be operationally defined as having a Mini Mental State Examination (MMSE) score greater or equal to 10.
Subjects must be on stable cognitive and psychoactive medication regimen for the preceding four weeks of enrollment.
Subjects must have a responsible study partner that either lives with them or is in regular contact with them at least 4 out of 7 days per week.
Disqualifiers
Any other condition (other than the primary diagnosis), which in the opinion of the investigators might contribute to the syndrome of dementia or complicate its assessment.
active medical disorder that could preclude participation in this protocol
Women who are pregnant or are breast feeding
severe renal impairment as defined by glomerular filtration rate (GFR) less than 30 (may have increased radiation exposure with the DaTscan).
Trial design
Treatments tested in this trial
- DaTscan
- F18-AV-45
- FDG-PET
- APOE genotype
- Polysomnogram
- Clinical Assessment
Treatment groups
76 Participants
are divided into 3 treatment groupsSponsors and collaborators
Douglas Scharre
Lead sponsor
Ohio State University
Sponsor institution
Avid Radiopharmaceuticals
Collaborator
Mangurian Foundation
Collaborator
Source ClinicalTrials.gov